Barrett & Company Inc. Sells 496 Shares of CVS Health Co. (NYSE:CVS)

Barrett & Company Inc. reduced its holdings in shares of CVS Health Co. (NYSE:CVS) by 8.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,678 shares of the pharmacy operator’s stock after selling 496 shares during the quarter. Barrett & Company Inc.’s holdings in CVS Health were worth $255,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CVS. Hotchkis & Wiley Capital Management LLC raised its holdings in CVS Health by 34.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 11,897,034 shares of the pharmacy operator’s stock valued at $748,085,000 after acquiring an additional 3,071,613 shares in the last quarter. ARGA Investment Management LP raised its holdings in shares of CVS Health by 7,567.7% during the 4th quarter. ARGA Investment Management LP now owns 2,402,901 shares of the pharmacy operator’s stock worth $107,866,000 after buying an additional 2,371,563 shares in the last quarter. State Street Corp raised its holdings in shares of CVS Health by 3.6% during the 3rd quarter. State Street Corp now owns 56,527,909 shares of the pharmacy operator’s stock worth $3,554,475,000 after buying an additional 1,989,066 shares in the last quarter. TOMS Capital Investment Management LP bought a new stake in CVS Health during the 3rd quarter worth $121,987,000. Finally, Pathway Financial Advisers LLC grew its position in CVS Health by 5,864.2% during the 3rd quarter. Pathway Financial Advisers LLC now owns 1,730,343 shares of the pharmacy operator’s stock worth $108,804,000 after acquiring an additional 1,701,331 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Down 2.7 %

CVS stock opened at $54.20 on Friday. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $80.75. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. The stock’s 50 day moving average is $50.90 and its 200-day moving average is $56.02. The firm has a market capitalization of $68.21 billion, a PE ratio of 13.76, a P/E/G ratio of 0.62 and a beta of 0.61.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.01. The business had revenue of $95.43 billion for the quarter, compared to analyst estimates of $92.72 billion. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. CVS Health’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the company posted $2.21 earnings per share. Sell-side analysts expect that CVS Health Co. will post 5.14 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.91%. The ex-dividend date was Thursday, January 23rd. CVS Health’s payout ratio is 67.51%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on CVS shares. Piper Sandler reduced their price objective on CVS Health from $72.00 to $64.00 and set an “overweight” rating on the stock in a research report on Monday, November 25th. TD Cowen upped their price target on CVS Health from $73.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, November 25th. StockNews.com lowered CVS Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Mizuho reduced their price target on CVS Health from $73.00 to $66.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Finally, UBS Group upped their price target on CVS Health from $60.00 to $62.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.12.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.